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Abstract.  Thrombospondin, the most abundant pro- 
tein of platelet ot granules, is a biosynthetic product of 
a  variety of connective tissue cells and a component of 
many extracellular matrices.  In this study, throm- 
bospondin distribution in bone was investigated using 
a  monoclonal antibody specific for the human protein. 
Thrombospondin was localized in osteoid of un- 
demineralized, frozen sections of fetal subperiosteal 
bone, and identified as a component of mineralized 
bone matrix of neonatal and/or young (growing) bone 
of many animal species by Western blot analysis. 
Adult human bone cells were demonstrated to contain 
mRNA for thrombospondin by hybridization of a 
cDNA thrombospondin probe to a  6.1  kb mRNA. 
Pulse-chase experiments indicated that the protein was 
synthesized and the majority was secreted from os- 
teoblastic cells. Treatment of the cells with TGF-/3 
(0.01-10  ng/ml) slightly decreased total thrombospon- 
din synthesis, but caused an increase in the retention 
on newly synthesized thrombospondin in the cell 
layer/matrix fraction. In cell attachment assays, throm- 
bospondin mediated adhesion, but not spreading of 
adult human bone cells. 
T 
HROMBOSPONDIN,  a  trimeric  molecule with Mr  = 
450,000,  is  composed  of inter-  and  intramolecular 
disulfide linked monomeric subunits of ~150 kD, with 
a minor globular domain at the amino terminus connected 
by an intervening stalk to a major globular region at the car- 
boxyl terminus.  Distinct binding regions have  been  iden- 
tiffed, and analysis of the amino acid sequence determined 
from cDNA clones (15, 31, 35) has revealed many sequence 
homologies with proteins  associated with clot formation, 
and with connective tissue matrices (reviewed in 20, 34, 40, 
59). The amino terminus contains a heparin binding region 
(13, 36, 47) with a sequence similar to fibrinogen (15). The 
stalk region contains a collagen binding site (33, 47) and a 
cysteine-rich region involved in disulfide bonding (21), and 
shares sequence homology to the precursor amino terminal 
extensions of the o~1 chain of types I and III collagens and 
to von Willebrand factor (27). The stalk region also contains 
binding sites for thrombin (11), fibrinogen (4, 12, 47), fibro- 
nectin (33,  47),  laminin (47),  plasminogen (47, 57),  and 
plasminogen activator (58).  In addition, this region contains 
sequence homologies with circumsporozoite protein from 
Plasmodiumfalciparum and EGF (35).  The carboxy globu- 
lar domain contains a  Ca  ++ binding region homologous to 
calmodulin, paralbumin, and fibrinogen (36), but due to sev- 
eral sequence differences, the molecular conformation is not 
comparable to the E-F hand structure identified in calmodu- 
lin. This region also contains RGD (35), a sequence that has 
been implicated in cell attachment, and indeed, thrombo- 
spondin appears to mediate cell attachment in a variety of 
cell types (53, 64, 65).  However,  it is not clear what role 
the RGD sequence plays in thrombospondin-mediated cell 
attachment. The most carboxy terminal portion of this do- 
main appears to be involved in mediating platelet aggregation 
(3, 14, 38) and binds to the histidine-rich glycoprotein of se- 
rum (39). 
Although first identified as a major protein of  human plate- 
let ct granules (2) and presumably a product of  the megakary- 
ocyte, thrombospondin is widely distributed in tissues (69), 
and is also produced by a variety of cell types including en- 
dothelial cells (35, 45, 46, 52), fibroblasts (28),  monocytes 
and  macrophages  (29),  aortic  smooth muscle cells  (52), 
granular type II pneumocytes (55), keratinocytes (65,  68), 
and glial cells (1). In this study, thrombospondin was iden- 
tified as a biosynthetic product of bone cells that becomes in- 
corporated into the mineralized matrix of bone. 
Materials and Methods 
Indirect Immunofluorescence 
Identification of  thrombospondin in the osteoid layer of  developing bone was 
determined by indirect immunofluorescence as described previously (67). 
Undemineralized, frozen sections (10 ~t thickness) of subperiosteal fetal bo- 
vine (5 mo gestation) and fetal  human (,x,4 mo gestation) bone were in- 
cubated with a  1:20 dilution of monoclonai mouse anti-human platelet 
thrombospondin ascites fluid containing ~7 mg/ml IgG (kindly provided by 
Dr. Deane E  Mosher, University of Wisconsin), and subsequently with a 
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purified IgG per milliliter) (Organon Teknika-Cappel, Malvern, PA).  For 
comparative purposes, similar sections were reacted with monoclonal mouse 
anti-bovine osteonectin (6) (",,6 mg/ml IgG per milliliter of ascites fluid) 
and normal mouse serum (1:10 dilution, control). Sections were examined 
with a Leitz ultraviolet microscope equipped with a 35-ram camera. Pho- 
tomicrographs of antibody and normal mouse serum-treated sections were 
exposed and processed under identical conditions. 
Western Blot Analysis of  Mineralized Matrix Extracts 
Bone from a variety of animal species was processed as described in detail 
elsewhere (62). Samples were initially extracted with buffered 4 M guani- 
dine hydrochloride containing protease inhibitors ("G" extract) to remove 
cellular components and proteins not intimately associated with mineral and 
subsequently with the same solvent but containing 0.5 M  EDTA ("E" ex- 
tract) to extract proteins bound to hydroxyapatite. The mineralized matrix 
proteins were subjected to electrophoresis on 12 % polyacrylamide gels (32) 
with minor modifications (18) and electrotmnsferred on to nitrocellulose 
(63). Immunodetection of thrombospondin in these Western blots was per- 
formed as described previously (63)  with minor modifications (30) using 
a  1:2,000 dilution of monoclonal mouse anti-human thrombospondin and 
a  1:2,000 dilution of peroxidase-conjugated rabbit anti-mouse IgG. 
Bone Cell Culture 
Cultures of fetal (generously provided by Dr. Jeffrey B. Kopp, National In- 
stitute of Dental Research, Bethesda, MD) and adult human bone cells were 
established as previously described with minor modifications (23). Femoral 
subperiosteal scrapings (from prenatal material >14 wk gestational age) or 
trabecular bone (generally from femoral heads removed during hip replace- 
ment) were minced into very small fragments (~1  ×  1 nun) and washed 
extensively with serum-free nutrient medium to remove blood and soft con- 
nective tissue. The washed fragments were then treated with 250 U/ml bac- 
terial coUagenase (Type IV; Sigma Chemical Co., St. Louis, MO) for 2 h 
at 37°C with constant rotation. The fragments were washed extensively with 
serum-free medium to remove cells released by the collagenase. The treated 
fragments were placed in calcium-free DME (Biofluids,  Inc., Rockville, 
MD)  containing 4.5  g  glucose/liter,  10%  heat-inactivated FBS  (Gibco 
Laboratories, Grand Island, NY),  100 U/ml penicillin, 100 ttg/ml strep- 
tomycin sulfate, and 50/~g/ml ascorbic acid. Due to the presence of FBS, 
the final calcium concentration was ,x,0.2 mM. Cultures were maintained 
in a humidified atmosphere of 90%  air,  10%  CO2  (to obtain appropriate 
pH levels in DME) and the medium was replaced every 2-3 d. After ",,2 
wk, cells emerged from the chips, and after another 1-2 mo, the cultures 
became confluent. The cells were passaged by release with Typsin-EDTA 
(Gibco Laboratories) and plated at specific densities as noted below in DME 
replete with calcium and containing the same additives as noted above 
("complete"  medium). Previous studies have indicated that these cultures are 
osteoblastic in nature based on their high levels of alkaline phosphatase ac- 
tivity, cAMP formation in response to parathyroid hormone, and the biosyn- 
thesis of an extracellular matrix containing the appropriate proteins (23). 
Isolation of mRNA and Northern Blot Analysis 
mRNA was isolated from the adult human bone cell cultures, as well as from 
cultures of human skin fibroblasts, periodontal ligament cells, and gingival 
cells as previously described (8, 71). In addition, mRNA was also isolated 
from human decidual tissue (66). Equal amounts of isolated mRNA (10 ttg) 
were subjected to electrophoresis  in 1.2 % formaldehyde agarose gels, which 
were subsequently stained with ethidium bromide to determine that similar 
amounts of  28S ribosomal RNA were present in each sample (44). Northern 
blots were prepared and hybridized with nick-translated eDNA probes (~1 
×  107 cpm) specific for human platelet thrombospondin (starting 115 bases 
upstream from the start codon to 800 bases beyond the stop codon), gener- 
ously  provided by  Dr.  William  A.  Frazier (Washington University, St. 
Louis, MO), and then with a eDNA probe for chick B-actin (9) under strin- 
gent conditions (44). The blots were exposed to x-ray film for analysis of 
hybridization of the probes to mRNA present in the samples for 16 h at 
-70°C. 
Protein Labeling 
Pulse-chase analysis of protein biosynthesis was performed on cells plated 
at an initial density of 40,000  cells/cm  2 in 35-mm dishes. After 24 h of 
recovery, the medium was removed and the ceils incubated for 48 h in the 
same medium but also containing 10 mM/~-glyeerol phosphate, ITS (insu- 
lin, transferrin, and selenium, all at 5 ttg/ml) (Collaborative Research, Lax- 
ingtun, MA), and  100/zg/ml ascorbic acid. After a  1-h preincubation in 
DME without glutamine and leucine, but with 10% dialyzed FBS and other 
additives noted above, the cells were pulse-labeled with 10/zCi/ml each of 
L-[lac(u)]leucine  (337.1  mCi/mmol) and  L-[laC-(U)]proline (262  mCi/ 
mmol New England Nuclear, Boston, MA) for 10 min. The cultures were 
then washed three times with complete medium, and incubated for various 
time points up to 12 h. At each time point, the medium and cell layer were 
separated and the cell layer was washed three times with PBS containing 
0.01 M EDTA, and 0.01 M  PMSF, and the first wash was combined with 
the medium fraction. The samples were stored frozen until analyzed. 
Modulation of Protein Biosynthesis by TGF-[3 
Cells were plated at a density of 25,000  cells/cm  2 and allowed to recover 
for 24 h in complete medium. Preliminary experiments indicated that the 
secretory capacity of the human bone cells is greatly reduced by incubation 
in serum-free medium, even for short periods of time, and consequently 
treatment with TGF-/~ was performed in the presence of 2 % heat-inactivated 
FBS, a level of serum found to support protein secretion. The cells were 
washed twice in complete medium containing 2% FBS and incubated for 
24 h before the addition of fresh medium containing increasing doses of 
TGF-/3 (kindly provided by Dr. Anita B. Roberts, National Cancer Institute, 
National Institutes of Health, Bethesda, MD) ranging from 0.01 to 10 ng/ml. 
After 24 h, the cultures were incubated for an additional 6 h with 5/~Ci/ml 
each of L-[t4c(U)]leucine and L-[t4C(U)]proline as described above. At the 
end of the incubation, the medium and cell layer fractions were separated, 
and stored frozen until analyzed further. 
Immunoprecipitation of  Radiolabeled Proteins 
After thawing, medium and cell layer fractions were processed for immuno- 
precipitation in the presence of  detergents using protein A-Sepharose (Phar- 
macia Fine Chemicals, Piscataway,  NJ) as described elsewhere (25). The 
medium was diluted 3:1 4x immunoprecipitation buffer (Ix =  0.05 M Tris- 
HCI, pH 7.4, 0.15 M sodium chloride, 1% Triton X-100, Ix sodium deoxy- 
cholate, 0.1% SDS, 0.1% aprotinin), and the cell layer was scraped into and 
extracted with 2x  immunoprecipitation buffer,  and subsequently diluted 
with an equal volume of water.  Both fractions were centrifuged to remove 
debris. Aliquots of both medium and cell layer fractions were used for 15% 
TCA precipitation to determine incorporation of isotopic precursors and for 
electrophoretic separation of the  total  population of radiolabeled poly- 
peptides. For immunoprecipitation using monoclonal mouse anti-human 
thrombospondin, the remainder of the sample was used for the pulse-chase 
analysis, and equal amounts of radioactivity were used from samples treated 
with and without TGF-/3. After reduction of disulfide bonds with DTT, 
immunoprecipitates were subjected to electrophoresis  on 4-20% polyacryl- 
amide gradient gels (32)  with minor modifications (18),  and radioactive 
polypeptides visualized by fluorography (7). In some experiments, radiola- 
beled polypeptides were quantitated by excising them from gels and solubi- 
lizing the radioactivity and scintillation spectroscopy. 
Cell Attachment Assay 
The ability of thrombospondin to mediate osteoblast cell attachment in vitro 
was assessed essentially as described by Roberts et al. (54).  Proteins, in- 
cluding serum-free conditioned medium of adult human bone cell cultures, 
human osteopontin (1 #g/ml), purified as described previously (19), throm- 
bospondin, kindly provided by Dr. David D. Roberts (at 10 and 50/zg/ml), 
and BSA (500 p.g/ml) were dissolved in PBS containing 1 mM CaCl2,  and 
10 ~1 of these solutions were applied to bacteriological dishes (resulting in 
a protein-coated area of 3 ram2).  Each 60-mm bacteriological plate con- 
tained three "dots" of each protein tested. After a  16-h incubation at 4°C, 
the solutions were removed by suction and the plates were washed with 50 
mM Tris-HCl, pH 7.8, 110 mM NaCI, 5 mM CaC12, 0.1 mM PMSF, !% 
BSA for 30 min at room temperature, and then three times with serum-free 
DME/Ham's F12  (1:1) containing 0.5%  ITS+  (insulin,  transferrin,  and 
selenium [2.5 #g/ml], BSA [500 #g/ml], and linoleic acid [0.5 #g/ml]) (Col- 
laborative Research) with glutamine, penicillin/streptomycin, and ascorbic 
acid (DME/HF12). Adult human bone cells were preincubated for 3 h with 
DME/HF12 containing 10 #g/ml cycloheximide  to inhibit protein synthesis, 
released by Trypsin-EDTA, washed twice, and seeded into the prepared 60- 
mm plates containing the 3-mm  2 protein-coated areas at a density of 40,000 
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munofluorescence. Undemineralized,  frozen sections 
(10  #m) of fetal  subperiosteal  bone (D)  were  first 
reacted  with  either  monoclonal  anti-human throm- 
bospondin (A) or anti-bovine osteonectin (B) (1:20 di- 
lution),  and  subsequently  with  fluorescein-labeled 
rabbit anti-mouse IgG (1:16). The sections were viewed 
with a Leitz ultraviolet microscope,  and photomicro- 
graphs taken using Kodak 1600 ASA film. Exposure 
times were 43 (thrombospondin) and 30 s (osteonec- 
tin).  Sections exposed to normal mouse  serum  (C) 
were photographed  for equivalent and longer expo- 
sure times and showed no reactivity. 
cells/cm  z in DME/HFI2 containing  cycloheximide.  After incubation for 
various time intervals,  the plates were washed three times with PBS to re- 
move unattached  cells,  fixed with 100% methanol at  -20°C for 30  min, 
and stained  with Giemsa. 
Results 
Identification of Thrombospondin  in Bone 
Initially, the presence of thrombospondin in developing bone 
(Fig.  1 D) was investigated by indirect immunofluorescence 
(Fig.  1). Immunoreactivity with the monoclonal antithrom- 
bospondin (Fig. 1 A) was localized to the osteoid layer on the 
surface of mineralized matrix in fetal bovine subperiosteal 
bone, a pattern similar to that found using a monoclonal anti- 
body against bovine osteonectin (Fig.  1 B). Identical results 
were also found for fetal human bone (data not shown). The 
cells embedded in the mineralized matrix (osteocytes) were 
also positive, but their reactivity was not as intense as that 
found with antiosteonectin. The mineralized matrix was only 
weakly  reactive with  both  antibodies  possibly due  to  the 
presence of hydroxyapatite which blocks access if the anti- 
body to the proteins in the mineralized bone matrix. No reac- 
tion was noted with normal mouse serum (Fig.  1 C). 
Subsequently, neonatal and young bone from a variety of 
animal species were sequentially extracted first by dissocia- 
tive, and then with dissociative and demineralizing condi- 
tions to determine if thrombospondin is a mineralized matrix 
protein. Thrombospondin, detected by Western blot analysis 
using monoclonal anti-human thrombospondin (Fig. 2), was 
readily apparent in human, monkey, ovine, and avian bone 
matrix  extracts.  Relatively  less  thrombospondin  was  de- 
tected in samples from bovine, porcine, canine, rat, mouse, 
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blot. Mineralized  matrix proteins isolated  from a number 
of animal species as described in Materials and Meth- 
ods were subjected to electrophoresis on  12%  poly- 
acrylamide gels, and transferred by electroblotting to 
nitrocellulose. The blot was initially reacted with mono- 
clonal anti-human thrombospondin (1:2,000), then with 
peroxidase-conjugated rabbit anti-mouse  IgG, and fi- 
nally with peroxidase substrate. 
and rabbit bone samples.  However, it should be noted that 
it is difficult to determine absolute amounts by this analysis 
due to  species differences. Taken together with the histo- 
chemical data, it is apparent that thrombospondin is a com- 
ponent of both osteoid and mineralized bone matrix. 
Identification of Thrombospondin as an Osteoblastic 
Cell Product 
Thrombospondin is not generally found free in the circula- 
tory  system,  and  consequently would  not adsorb to  bone 
hydroxyapatite from serum as is the case with serum o~2-HS 
glycoprotein, a protein synthesized in the liver and concen- 
trated in bone. However, it is possible that thrombospondin 
might be synthesized by cell types other than osteoblasts that 
are adjacent to bone and then entombed within bone during 
the mineralization process. To determine if osteoblasts con- 
tribute,  at least in part,  to the thrombospondin content of 
bone, human bone cell cultures were established and used to 
identify thrombospondin mRNA, and to study the biosynthe- 
sis of this molecule. Northern blot analysis using a cDNA 
probe specific for thrombospondin revealed a 6.1-kb mRNA 
in human bone cells, as well as in skin fibroblasts, and in gin- 
gival and periodontal ligament cells (Fig.  3). Interestingly, 
thrombospondin mRNA was not found in human decidual 
tissue of the uterus, although relatively equal amounts of ac- 
tin mRNA  and  28S  ribosomal  RNA  were present  in  this 
sample. 
In light of recent evidence that mRNA may be present but 
not translated by cells under certain conditions (5), the bio- 
synthesis  of thrombospondin  by  osteoblasts  was  demon- 
strated by pulse-chase analysis (Fig.  4).  Thrombospondin 
monomer, detected by immunoprecipitation, was  found in 
the pulse-labeled cell layer fraction with an apparent molec- 
ular weight of "o180,000  and  was  not detectably different 
from  the  secreted  molecule.  During  the  chase  intervals, 
thrombospondin levels in the cell layer were maximal be- 
tween 1 and 2 h.  However, significant levels remained cell 
layer-associated after extended chase intervals, and 'M0% 
of the maximal level was present after a 12-h chase, as deter- 
mined by quantitation of radioactivity from solubilized gel 
slices. Secretion into the medium was detected after a 40-min 
chase, and maximum levels were achieved at 1 h and gradu- 
ally fell to '~50% of the maximum level after a  12-h chase. 
This pattern of synthesis and secretion is somewhat slower 
than that of type I procollagen and osteonectin, but similar 
to that of fibronectin, as determined by sequential immuno- 
precipitation (24) of these proteins from these same samples 
(R  Gehron Robey, unpublished results). 
Effect of TGF-~ on Thrombospondin Biosynthesis 
Since TGF-/3 is a regulator of matrix protein production in 
many cell culture systems (48, 51, 70), its effects on throm- 
bospondin production by fetal and adult bone cells were in- 
vestigated.  In the presence of 2 % FBS, exogenous TGF-~ 
does  not  stimulate  mitogenesis by 24  h.  With  increasing 
doses of TGF-/~ ranging from 0.01 to 10.0 ng/ml, total protein 
synthesis was slightly inhibited in both fetal and adult human 
bone cells (at 10 ng/ml, 78.5  +  2.1% and 63 +  1.4% of fetal 
and adult cells, respectively; n =  two experiments), as deter- 
mined by TCA precipitation of aliquots of medium and cell 
layer fractions.  Total  thrombospondin biosynthesis, deter- 
mined  by  quantitation  of radioactive  immunoprecipitated 
thrombospondin was marginally inhibited (10 ng/ml, 94  + 
4.2% and 88.2 +  2.8% of fetal and adult control levels). In- 
terestingly, the amount of thrombospondin associated in the 
cell layer/matrix fraction appeared to increase in TGF-/3- 
treated  samples  (Fig.  5).  Others  have  noted  a  marked 
stimulatory effect of TGF-~ on matrix protein metabolism in 
serum-free conditions in  cells derived from other species 
(48,  51,  70).  The  biological  significance of the  marginal 
effects observed in human bone cells in the presence of 2 % 
FBS is not yet clear. 
Effect of Thrombospondin on Osteoblast 
Cell Attachment 
The effect  of thrombospondin in mediating adult human bone 
cell attachment was investigated and compared to other pro- 
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bospondin cDNA. mRNA ("o10 #g) was isolated 
and subjected to electrophoresis on 1.2 % formal- 
dehyde agarose gels. Ribosomal RNA was visual- 
ized by ethidium bromide to determine that rough- 
ly equivalent amounts of material were present in 
each lane. The RNA was blotted onto nitrocellu- 
lose and reacted first with human thrombospondin 
cDNA and then with chick B-actin cDNA probes 
under stringent conditions. The blots were exposed 
to x-ray film for 16 h at  -70°C. 
Figure 4.  Pulse-chase analysis of thrombospondin biosynthesis. Cultures of adult human bone cells (50,000 cells/cm  2 in 35-mm dishes) 
were preincubated in ieucine-free DME containing 10% dialyzed FBS and supplements (see Materials and Methods) for 1 h and then pulse- 
labeled for 10 min with 5 #Ci/ml each of [~4C]leucine and [~4C]proline. After washing three times, the cultures were incubated from vari- 
ous time intervals in complete medium. Thrombospondin immunoprecipitations, as well as equal aliquots of the medium and cell layer 
fractions were subjected to electrophoresis  on 4-20% polyacrylamide  gradient gels after reduction of disulfide  bonds with DTT. Radioactive 
polypeptides were visualized by fluorography. 
Gehron Robey et al. Thrombospondin and Bone  723 Figure 5.  Effect of TGF-B on thrombospondin  biosynthesis.  Fetal and adult human bone cells (25,000 cells/cm 2 in six-well plates) were 
incubated in the complete medium with 2% FBS for 24 h before treatment with TGF-/3 (0.01 ng,  10 ng/ml) for an additional 24 h. The 
cultures were then radiolabeled with 5/zCi/ml each of ['4C]leucine and [~4C]proline in leucine-free DME with 2% dialyzed FBS and sup- 
plements (see Materials and Methods) for 6 h. Incorporation of isotope into the medium and cell layer fractions was determined by 15 % 
TCA precipitation, and equal levels of radioactivity were used for thrombospondin immunoprecipitation and for analysis of  the total popula- 
tion of radiolabeled polypeptides.  Samples were subjected to electrophoresis  on 4-20% polyacrylamide gradient gels and visualized by 
fluorography. 
teins known to exhibit this property, including  osteopontin 
(also known as bone sialoprotein I and 44-kD phosphopro- 
tein). Osteopontin (49, 50) has been found to be a cell attach- 
ment  protein  for  both  a  rat  osteosarcoma cell  line,  ROS 
17.0/2.8 (49), and for human periodontal ligament cells (60). 
Bone cells were found to attach to areas coated with serum- 
free bone cell-conditioned medium, osteopontin, and throm- 
bospondin  (Fig.  6).  However, differences in the pattern of 
attachment were noted.  Although similar numbers of cells 
attached to the various substrates (as determined by counting 
of cells  in  several  fields),  bone  cell-conditioned  medium 
mediated cell attachment, spreading, and migration (as noted 
by the  development of pseudopodial  processes).  Cells  at- 
tached to osteopontin (93.3  +  3.2%  of the number of cells 
attached to conditioned medium-coated areas; n  =  three ex- 
periments), but remained ellipsoidal and relatively station- 
ary. Cells attached in the thrombospondin-coated areas (85.5 
+  5.1%,  n  =  three experiments), but did not spread,  even 
upon prolonged (24 h)  incubation. 
Discussion 
Based on the results presented here,  it appears that throm~ 
bospondin is a previously unidentified component of osteoid 
and mineralized bone matrix.  Osteoblasts would appear to 
contribute to bone matrix thrombospondin, since these cells 
contain thrombospondin mRNA and  synthesize this mole- 
cule in vitro. However, other cell types associated with bone 
(endothelial cells, marrow stromal cells, etc.) may also con- 
tribute to this pool. 
Since its initial discovery (2), a multitude of studies sug- 
gest that thrombospondin may mediate the secondary (secre- 
tion-dependent) phase of platelet aggregation (3,  14, 22,  37, 
38).  Due to its many interactions with other matrix mole- 
cules, another potential function(s) may lie in the organiza- 
tion of the extracellular matrix of connective tissue cells. It 
was also suggested that in certain cell types, thrombospondin 
can even function as an autocrine growth factor (41). The role 
of this molecule in bone metabolism is not known,  but  in 
light of previous studies in other cell and tissue systems, it 
is interesting to speculate on its potential functions in bone. 
Since  the  major  (carboxy-terminal) globular  domain  of 
thrombospondin contains multiple Ca  ++ binding  sites,  it is 
possible the molecule may exert its function in bone via this 
property.  In  fact,  the  interaction  of calcium  with  throm- 
bospondin is not trivial. It has been found, for example, that 
the conformation of the major globular domain, in which the 
RGD sequence is buried,  is affected by the presence or ab- 
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bone cell-conditioned medium, osteopontin (1 #g/ml), and throm- 
bospondin  (50  /~g/ml) were dotted  onto  60-ram  bacteriological 
dishes (resulting in a 3-ram  2 area) and allowed to adsorb at 4°C 
overnight. The dishes were washed as described in the text and adult 
human bone cells, previously incubated in cycloheximide (10 #g/ 
rrd), were added at a density of 40,000 cells/cm  2 in DME/HF-12 
containing 0.5% ITS+ and cycloheximide. After a 2-h incubation 
at 37°C, the plates were carefully washed, fixed with 100% metha- 
nol at  -20°C, and stained with Giemsa. 
sence of Ca  ++ (16, 37).  In previous reports using fragments 
of the thrombospondin molecule, it was found that the amino 
terminus is  involved in cell spreading but that attachment 
does not occur unless the carboxy-terminal globular domain 
is  present (54).  Therefore, the ability of this  molecule to 
mediate cell attachment may be mediated by the ionic envi- 
ronment in which it is found. In fact, it has been found that 
keratinocytes  grown  in  low  calcium  medium  synthesize 
thrombospondin, and attach and spread on thrombospondin- 
coated substrates.  However, if the calcium concentration is 
increased, thrombospondin synthesis and cell attachment are 
reduced (65). It is not yet known how Ca  ++ levels regulate 
thrombospondin biosynthesis or cell attachment and spread- 
ing in osteoblasts. 
A fascinating aspect of thrombospondin is seen in recent 
studies of aortic smooth muscle cells, where stimulation of 
proliferation by PDGF selectively induces the production of 
certain proteins,  including thrombospondin (41,  42).  Fur- 
thermore, thrombospondin synergizes with EGF to increase 
proliferation (41), and if thrombospondin is inactivated (by 
blocking monoclonal antibodies) (43) or removed from the 
pericellular environment (by addition of  heparin which binds 
to thrombospondin), cell proliferation is decreased (41). In 
this study, it appeared that TGF-3 caused an increase in cell 
layer/matrix-associated thrombospondin in spite of a reduced 
total protein synthesis and a slight reduction in overall throm- 
bospondin synthesis. By analogy to the aortic smooth muscle 
system, it is possible that the mitogenic effects of TGF-/3 are 
mediated by thrombospondin. 
Of particuar interest is the possible interaction of throm- 
bospondin and  osteonectin. Osteonectin (SPARC,  BM-40, 
culture shock protein) has been identified in the o~ granules 
of platelets (61) and is released along with thrombospondin 
during platelet aggregation. A recent study has demonstrated 
that thrombospondin and osteonectin bind to one another 
(10). In many species, including man, osteonectin is the most 
abundant  noncollagenous  protein  in  bone.  Although  os- 
teonectin is 100-1,000 times more concentrated in bone com- 
pared to other connective tissues, it appears to be identical 
to proteins that have been identified in other tissues. It is syn- 
thesized by certain tissues during various stages of murine 
development (26), by certain basement membrane forming 
cells (17, 66), and in response to varying culture conditions 
(56).  In  general,  the expression and  accumulation of os- 
teonectin in nonbone sources in vivo, appears to be transient 
(presumably induced and  repressed by local factors), and 
related to stages of proliferation and/or maturation, whereas 
in bone, expression appears to be constitutive and the protein 
remains associated with extraceUular matrix.  The signifi- 
cance of the colocalization of thrombospondin and osteonec- 
tin in such different tissue systems (platelets and bones) is not 
yet known, but it is possible that these two molecules (along 
with  others)  create an  environment that  is  conducive for 
remodeling (e.g., wound repair), as particularly exemplified 
by bone, which is in a  constant state of remodeling (bone 
turnover). 
Clearly, much more investigation is needed to define the 
role of thrombospondin in bone, but the hints that nature has 
provided (colocalization of thrombospondin and osteonectin 
in platelets and bone) provide a direction for future compara- 
tive studies to identify common mechanisms in these two tis- 
sues that  may elucidate the  functions of these  interesting 
molecules. 
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